MAOA Overview
Molecule Name
Monoamine oxidase A
Synonyms
MAOA
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs2
Highest Development StageApproved
Target Synonym
EC 1.4.3，EC:1.4.3.4，Monoamine oxidase type A，Amine Oxidase [Flavin-Containing] A，MAO-A，MAOA，Monoamine Oxidase A，EC 1.4.3.4，BRNRS
Background
MAOA, Monoamine oxidase-A is an FAD-dependent mitochondrial enzyme, which, together with its isoenzyme MAO-B, catalyses the oxidative deamination of structurally diverse amines. MAOA is mainly involved in the metabolism of monoamine neurotransmitters, such as such as serotonin, dopamine, and norepinephrine. Inhibitors of MAOA are in clinical use for affective disorders and is approved to treat despression.
MAOA Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CB-2202 | CB-2202 | Phase 2 Clinical | Cennerv Pharma | Depressive Disorder, Major | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Toloxatone | MD-69276 | Approved | Umoril, Humoryl, Perenum | France | Depression | null | 1984-01-01 | Depression | Details | |
| Metaxalone (Primus Pharmaceuticals) | Approved | Primus Pharmaceuticals Inc | United States | Muscle Spasticity | Primus Pharmaceuticals Inc | 2015-06-01 | Muscle Spasticity | Details |